RecruitingNCT07662018

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors


Sponsor

M.D. Anderson Cancer Center

Enrollment

30 participants

Start Date

Jun 5, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.


Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Carboplatin, a drug called Docetaxel, and others for people with carboplatin, docetaxel, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGemcitabine (GEM)

Give by Iv

DRUGDocetaxel

Given by Iv

DRUGMelphalan

Given by IV

DRUGCarboplatin

Given by Iv


Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07662018


Related Trials